CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma.

Following the success of the COVID-19 vaccines, mRNA vaccines have now entered development for a wide range of infectious diseases. This Review discusses mRNA vaccine design considerations ...

Market is currently closed. Voting is open during market hours.

After hours: October 18 at 7:59 PM EDT ...

As of 10:59 AM EDT. Market Open.

View upcoming earnings forecasts and in-depth analysis of company forecasts.